Clinical Trials in Baltimore

Showing 8721-8740 of 23,476 trials

Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely

NCT02545127

Induction and support of lactation in women with preterm delivery and inadequate milk production.

Preterm DeliveryInadequate Milk Production

Ferring Pharmaceuticals4 participantsStarted May 2021

New Haven, Connecticut, United States • South Bend, Indiana, United States • Baltimore, Maryland, United States +7 more locations

COMPLETEDPhase 2< 1 mile

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

NCT03682770

Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing double-blind placebo-controlled food challenge (DBPCFC) at visit 16. Secondary objectives are: * To assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the cumulative tolerated dose (log transformed) of peanut protein during a post up-dosing DBPCFC at visit 16 * To assess whether dupilumab as (indefinite \[continuously\]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22 * To assess whether dupilumab as (limited \[previously\]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22 * To evaluate the safety and tolerability of dupilumab as adjunct to AR101 compared to placebo * To assess the effect of dupilumab (compared to placebo) as adjunct to AR101 on the change in peanut-specific Immunoglobulin E (sIgE), Immunoglobulin G (IgG), Immunoglobulin G4 (IgG4), and peanut-specific IgG4/IgE ratio * To assess if dupilumab increases the tolerability of AR101 as measured by the daily symptoms (electronic diary \[e-diary\]) during the up-dosing phase

Peanut Allergy

Regeneron Pharmaceuticals148 participantsStarted Oct 2018

Birmingham, Alabama, United States • Tucson, Arizona, United States • Little Rock, Arkansas, United States +22 more locations

Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Find Trials by Condition in Baltimore

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Systemic Biomarkers of Brain Injury From Hyperammonemia

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

ILLUMENATE Pivotal Post-Approval Study (PAS)

Omnibond vs Dermabond

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Pleconaril Enteroviral Sepsis Syndrome

Actuate 1901: 9-ING-41 in Myelofibrosis

Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria